AMD Announces "Advancing AI 2026"

News Highlights:

  • Advancing AI is AMD's flagship global AI event, bringing developers, customers, enterprise leaders and partners together, showcasing the latest advancements in AMD AI solutions.

www.AMD.com/" target="_blank" rel="nofollow">AMD (NASDAQ: www.AMD.com/" target="_blank" rel="nofollow">AMD) announced "www.AMD.com/en/corporate/events/advancing-ai.html" target="_blank" rel="nofollow">Advancing AI 2026," its flagship global AI event, will be held both in-person and livestreamed from the San Francisco Moscone Center on July 23, 2026. The event will provide the AI open ecosystem with blueprints for building, deploying and scaling AI powered by www.AMD.com/" target="_blank" rel="nofollow">AMD.

AMD leaders will join Chair and CEO Dr. Lisa Su, alongside AI ecosystem partners, customers and developers, to share how the company's end-to-end AI solutions, from silicon to software, are reshaping the AI and high-performance computing landscape.

The event will be hosted in-person on Thursday, July 23 and livestreamed on the AMD YouTube channel.

About AMD
AMD (NASDAQ: AMD) drives innovation in high-performance and AI computing to solve the world's most important challenges. Today, AMD technology powers billions of experiences across cloud and AI infrastructure, embedded systems, AI PCs and gaming. With a broad portfolio of AI-optimized CPUs, GPUs, networking and software, AMD delivers full-stack AI solutions that provide the performance and scalability needed for a new era of intelligent computing. Learn more at www.amd.com.


Contact: Brandi Martina AMD Communications +1 512-705-1720 Brandi.Martina@AMD.com Liz Stine AMD Investor Relations +1 720-652-3965 liz.stine@AMD.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AMD
The Conversation (0)
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of... Keep Reading...
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors,... Keep Reading...
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth... Keep Reading...

Interactive Chart

Latest Press Releases

Related News